By Associate Professor Anthony Michael Joshua

Journal articles

Ardolino L; Hansen A; Ackland S; Joshua A, 2020, 'Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies', Hormones and Cancer, 11, pp. 155 - 169, http://dx.doi.org/10.1007/s12672-020-00385-3

Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B, 2020, 'Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment', Epigenomics, 12, pp. 1317 - 1332, http://dx.doi.org/10.2217/epi-2020-0173

Joshua AM; Tannock IF, 2020, 'Oncology in 2050 – A Retrospective?', Oncologist, 25, pp. e1127 - e1130, http://dx.doi.org/10.1634/theoncologist.2019-0887

Wu S; Roden D; Al-Eryani G; Bartonicek N; Harvey K; Cazet A; Chan C-L; Junankar S; Hui M; Millar E; Beretov J; Horvath L; Joshua A; Stricker P; Wilmott J; Quek C; Long G; Scolyer R; Yeung B; Segara D; Mak C; Warrier S; Powell J; O'Toole S; Lim E; Swarbrick A, 2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073

Sridhar SS; Kolinsky MP; Gravis G; Mourey L; Piulats Rodriguez JMM; Romano E; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; De Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Qiu P; Schloss C; Yu EY, 2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.', Journal of Clinical Oncology, 38, pp. 5550 - 5550, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5550

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5500

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Hutton-Potts M; Joshua AM, 2020, '2017 ASCO position on the affordability of cancer drugs: Arguments for a major revision', JCO Oncology Practice, 16, pp. 211 - 214, http://dx.doi.org/10.1200/JOP.19.00763

Ala-Leppilampi K; Baker NA; McKillop C; Butler MO; Siu LL; Spreafico A; Abdul Razak AR; Joshua AM; Hogg D; Bedard PL; Leighl N; Oza AM; Parsons JA; Hansen AR, 2020, 'Cancer patients’ experiences with immune checkpoint modulators: A qualitative study', Cancer Medicine, 9, pp. 3015 - 3022, http://dx.doi.org/10.1002/cam4.2940

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178

Conway MR; Cherepanoff S; Joshua AM, 2020, 'The end of pathology as we know it? (vol 47, pg 163, 2019)', CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 48, pp. 274 - 274, http://dx.doi.org/10.1111/ceo.13720

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Alibhai SMH; Breunis H; Timilshina N; Hansen AR; Joshua AM; Warde PR; Gregg RW; Fleshner NE; Tomlinson G; Hotte SJ; Emmenegger U, 2020, 'The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 38, pp. 73 - 73, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.73

Schmidt AL; Anton A; Wong SS; Azad A; Kwan EM; Spain LA; Torres J; Muthusamy A; Parente P; Parnis F; Goh JC; Joshua AM; Pook DW; Gibbs P; Tran B; Weickhardt AJ, 2020, 'Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.', Journal of Clinical Oncology, 38, pp. 78 - 78, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.78

Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG, 2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, 10, http://dx.doi.org/10.1136/bmjopen-2019-033667

Rodriguez JMP; Patel S; Espinosa E; Pelster MS; Merino LDLC; Khoja LT; Joshua AM; Tebe C; Berrocal A, 2020, '1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials', Annals of Oncology, 31, pp. S764 - S764, http://dx.doi.org/10.1016/j.annonc.2020.08.1266

Romano E; Sridhar SS; Kolinsky MP; Gravis G; Mourey L; Piulats JM; Berry WR; Gurney H; Retz M; Appleman LJ; Boegemann M; de Bono JS; Joshua AM; Emmenegger U; Conter HJ; Laguerre B; Wu H; Qiu P; Schloss C; Yu EY, 2020, 'Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update', ANNALS OF ONCOLOGY, 31, pp. S512 - S513, http://dx.doi.org/10.1016/j.annonc.2020.08.879

Day D; Guo C; Kanjanapan Y; Tran B; Spreafico A; Joshua AM; Wang L; Abdul Razak AR; Leighl NB; Hansen AR; Butler MO; Siu LL; Desai J; Bedard PL, 2019, 'Survival in early phase immuno-oncology trials: Development and validation of a prognostic index', JNCI Cancer Spectrum, 3, http://dx.doi.org/10.1093/jncics/pkz071

Joshua AM; Tannock IF, 2019, 'Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome', Cancer Cell, 36, pp. 464 - 465, http://dx.doi.org/10.1016/j.ccell.2019.10.003

Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L, 2019, 'Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options', Asia-Pacific Journal of Clinical Oncology, 15, pp. 3 - 10, http://dx.doi.org/10.1111/ajco.13289

Balzer BWR; Cherepanoff S; Joshua AM; Giblin M; Conway RM; Anazodo AC, 2019, 'Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review', Ocular Oncology and Pathology, 5, pp. 387 - 395, http://dx.doi.org/10.1159/000497813

Bavi P; Siva M; Abi-Saab T; Chadwick D; Dhani N; Butany J; Joshua AM; Roehrl MH, 2019, 'Developing a pan-cancer research autopsy programme', Journal of Clinical Pathology, 72, pp. 689 - 695, http://dx.doi.org/10.1136/jclinpath-2019-205874

Brown B; Simes J; Boyer M; Hogg P; Joshua A; Young J, 2019, 'Embedding Research (and Evidence) in Cancer Healthcare - EnRICH', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S606 - S606, http://dx.doi.org/10.1016/j.jtho.2019.08.1273

Brown B; Simes J; Boyer M; Joshua A; Hogg P; Young J, 2019, 'Patterns of Care in a Prospective Clinical Cohort of Patients with Lung Cancer - Preliminary Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S880 - S880, http://dx.doi.org/10.1016/j.jtho.2019.08.1903

Brown B; Simes J; Boyer M; Hogg P; Joshua A; Young J; Brown C, 2019, 'Psychological Distress in Never, Ex, Current, and Passive Smokers Diagnosed with Lung Cancer - Analyses from the EnRICH Program', JOURNAL OF THORACIC ONCOLOGY, 14, pp. S326 - S327, http://dx.doi.org/10.1016/j.jtho.2019.08.656

Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM, 2019, 'Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', Oncologist, 24, pp. 1188 - 1194, http://dx.doi.org/10.1634/theoncologist.2018-0621

Green BJ; Nguyen V; Atenafu E; Weeber P; Duong BTV; Thiagalingam P; Labib M; Mohamadi RM; Hansen AR; Joshua AM; Kelley SO, 2019, 'Phenotypic profiling of circulating tumor cells in metastatic prostate cancer patients using nanoparticle-mediated ranking', Analytical Chemistry, 91, pp. 9348 - 9355, http://dx.doi.org/10.1021/acs.analchem.9b01697

Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM, 2019, 'Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study', Annals of Oncology, 30, pp. 1370 - 1380, http://dx.doi.org/10.1093/annonc/mdz176

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Neil Reaume M; Sandhu SK; Tan A; Hsiang Tan T; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ, 2019, 'Enzalutamide with standard first-line therapy in metastatic prostate cancer', New England Journal of Medicine, 381, pp. 121 - 131, http://dx.doi.org/10.1056/NEJMoa1903835

O’Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ, 2019, 'A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial', British Journal of Cancer, 120, pp. 1113 - 1119, http://dx.doi.org/10.1038/s41416-019-0474-x

Hotte SJ; Chi KN; Joshua AM; Tu D; Macfarlane RJ; Gregg RW; Ruether JD; Basappa NS; Finch D; Salim M; Winquist EW; Torri V; North S; Kollmannsberger C; Ellard SL; Eigl BJ; Tinker A; Allan AL; Beja K; Annala M; Powers J; Wyatt AW; Seymour L, 2019, 'A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205', Clinical Genitourinary Cancer, 17, pp. 201 - 208.e1, http://dx.doi.org/10.1016/j.clgc.2019.03.005

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, 16, pp. 397, http://dx.doi.org/10.1038/s41571-019-0212-6

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, 16, pp. 386 - 396, http://dx.doi.org/10.1038/s41571-019-0179-3

Massard C; Retz M; Hammerer P; Quevedo F; Fong PCC; Berry WR; Gurney H; Piulats JM; Joshua AM; Linch MD; Kolinsky MP; Romano E; Sridhar SS; Conter HJ; Augustin M; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5029

Fong PCC; Retz M; Drakaki A; Massard C; Berry WR; Romano E; De Bono JS; Feyerabend S; Appleman LJ; Conter HJ; Sridhar SS; Shore ND; Linch MD; Joshua AM; Gurney H; Wu H; Schloss C; Poehlein CH; Yu EY, 2019, 'Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5010

Yu EY; Massard C; Retz M; Tafreshi A; Carles J; Hammerer P; Fong PCC; Shore ND; Joshua AM; Linch MD; Gurney H; Romano E; Augustin M; Piulats JM; Wu H; Schloss C; Poehlein CH; De Bono JS, 2019, 'Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5027

Alibhai SMH; Breunis H; Gregg RW; Hansen AR; Warde PR; Timilshina N; Tomlinson G; Joshua AM; Fleshner NE; Emmenegger U, 2019, 'Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.', Journal of Clinical Oncology, 37, pp. 11510 - 11510, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.11510

Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO, 2019, 'Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2', Cancer Immunology, Immunotherapy, 68, pp. 773 - 785, http://dx.doi.org/10.1007/s00262-019-02307-x

Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL, 2019, 'Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities', Cancer, 125, pp. 1341 - 1349, http://dx.doi.org/10.1002/cncr.31999

Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A, 2019, 'Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001', Annals of Oncology, 30, pp. 582 - 588, http://dx.doi.org/10.1093/annonc/mdz011

Ardolino L; Joshua A, 2019, 'Immune checkpoint inhibitors in malignancy', Australian Prescriber, 42, pp. 62 - 67, http://dx.doi.org/10.18773/austprescr.2019.012

Luke JJ; Tabernero J; Joshua A; Desai J; Varga AI; Moreno V; Gomez-Roca CA; Markman B; De Braud FG; Patel SP; Carlino MS; Siu LL; Curigliano G; Liu Z; Ishii Y; Wind-Rotolo M; Basciano PA; Azrilevich A; Gelmon KA, 2019, 'BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).', Journal of Clinical Oncology, 37, pp. 358 - 358, http://dx.doi.org/10.1200/jco.2019.37.7_suppl.358

Yu EY; Massard C; Retz M; Tafreshi A; Carles Galceran J; Hammerer P; Fong PCC; Shore ND; Joshua A; Linch MD; Gurney H; Romano E; Augustin M; Piulats JM; Wu H; Schloss C; Poehlein CH; De Bono JS, 2019, 'Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 37, pp. 145 - 145, http://dx.doi.org/10.1200/jco.2019.37.7_suppl.145

Conway MR; Cherepanoff S; Josua AM, 2019, 'Managing ocular surface neoplasia without biopsy: The end of pathology as we know it?', Clinical and Experimental Ophthalmology, 47, pp. 163 - 164, http://dx.doi.org/10.1111/ceo.13475

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell M; Chow K; Sherwin B; Stayner LA; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A, 2019, 'Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials', European Journal of Cancer, 107, pp. 1 - 7, http://dx.doi.org/10.1016/j.ejca.2018.10.017

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Sattar S; Alibhai SMH; Brennenstuhl S; Kulik M; MacDonald ME; McWatters K; Lee K; Jang R; Amir E; Krzyzanowska MK; Joshua AM; Monette J; Wan-Chow-Wah D; Puts MTE, 2019, 'Health status, emergency department visits, and oncologists’ feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial', Journal of Geriatric Oncology, 10, pp. 169 - 174, http://dx.doi.org/10.1016/j.jgo.2018.06.014

Back to profile page